Information from the section 3 VERIFY trial had been shared on the 2025 ASCO Annual Assembly, the place investigators famous that rusfertide could also be a possible remedy possibility for sufferers with polycythemia vera, a sort of blood most cancers, in keeping with Dr. Aaron Gerds. It’s because the investigational therapeutic agent was capable of cut back or remove the necessity for phlebotomies, a process which removes further blood cells from the physique through the use of a needle to take blood from the vein, enhancing high quality of life and symptom management.
To additional talk about this knowledge, Gerds sat down for an interview with CURE, through which he highlighted what sufferers ought to know in regards to the VERIFY trial following the ASCO Assembly.
Transcript:
What ought to sufferers know in regards to the VERIFY trial, introduced at this yr’s ASCO Annual Assembly?
The ASCO Annual Assembly is all the time a difficult convention for these of us in hematology. Hematologic neoplasms usually characterize a smaller portion of the bigger ASCO assembly, and typically you actually must sift via quite a few abstracts to search out one thing really spectacular. Nevertheless, this yr, we had the lucky occasion of a hematologic malignancy being featured as a plenary summary. That is the distinguished session the place they choose the highest few abstracts to current to an enormous, huge crowd, genuinely highlighting the significance of this analysis.
The truth that it issues polycythemia vera is especially important for a considerably uncommon blood most cancers that always does not obtain a lot consideration. It is a illness we have identified an ideal deal about for a very long time however have comparatively few permitted therapies. As of at the moment, there are solely two FDA-approved medication for polycythemia vera: Jakafi (ruxolitinib), permitted within the second-line setting, and Besremi (ropeginterferon alfa-2b-njft), permitted for all settings. Given this restricted therapeutic panorama, a brand new, efficient drug like rusfertide, which presents a totally completely different mechanism, is completely warranted for the sphere.
The trial introduced at this yr’s ASCO assembly was a traditional, definitive section 3 registration research. It included sufferers who obtained the drug and people who didn’t, permitting for an intensive comparability with all of the statistical energy wanted for regulatory approval. This was the trial in query.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
